Hyperbaric Oxygen Therapy in Diabetic Foot
NCT Number: NCT06502808
Acronym: HBOTDF
Status: COMPLETED
Study Type: OBSERVATIONAL
Conditions: Diabetic Foot Ulcer Neuropathic
Interventions: OTHER: Hyperbaric oxygen therapy
Sponsor: National Polytechnic Institute, Mexico
Sex: ALL
Age: ADULT, OLDER_ADULT
Enrollment: 15
Study Design: Observational Model: |Time Perspective: p
Start Date: 2019-01-15
Completion Date: 2020-07-15
Locations: Modesto Gómez López, Mexico City, Cdmx, 11340, Mexico

Summary:
This study seeks to assess changes in genes that are related to inflammation and oxidative stress in patients with type 2 Diabetes with diabetic foot treated with hyperbaric chamber

Primary Outcome Measures: Gene expression of superoxide dismutase 1/ SOD1, . Blood samples were collected and relative gene expression was assessed by quantitative real time polymerase chain reaction (qPCR)., The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.|Gene expression of superoxide dismutase 2, Blood samples were collected and relative gene expression was assessed by quantitative real time polymerase chain reaction (qPCR)., The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.|Glutathione Peroxidase (GPX2), Blood samples were collected and relative gene expression was assessed by quantitative real time polymerase chain reaction (qPCR)., The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.|Interleukin-1β (IL-1β), Blood samples were collected and relative gene expression was assessed by quantitative real time polymerase chain reaction (qPCR)., The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.|Interleukin-4 (IL-4), Blood samples were collected and relative gene expression was assessed by quantitative real time polymerase chain reaction (qPCR)., The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.|Interleukin-12 (IL-12), Blood samples were collected and relative gene expression was assessed by quantitative real time polymerase chain reaction (qPCR)., The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.|NLRP3 inflammasome (NOD-, LRR- and pyrin domain-containing protein 3), Blood samples were collected and relative gene expression was assessed by quantitative real time polymerase chain reaction (qPCR)., The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.|Tumor necrosis factor alpha (TNF-α), Blood samples were collected and relative gene expression was assessed by quantitative real time polymerase chain reaction (qPCR)., The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.